Cardiovascular Generic Drugs: Prospects and Opportunities to 2012Espicom Healthcare Intelligence
December 31, 2007
186 Pages - SKU: ESPI1657179
Additional InformationWith a number of first line therapies coming off-patent in the next 5 years the prospects for generic producers are good
Cardiovascular disease is a global problem. In the developed world, its prevalence is linked to our increasingly unhealthy lifestyle, with risk factors including lack of exercise, overweight and obesity, and smoking. It is also linked to diabetes, a condition affecting an increasing number of people worldwide which greatly increases the risk of developing heart disease. The main areas targeted by cardiovascular drugs are high blood pressure and elevated blood cholesterol levels.
While the cholesterol management market remains dominated by statins and fixed-dose combination drugs containing statins, the market for drugs to treat hypertension covers a number of classes, such as beta blockers, ACE inhibitors, angiotensin-II receptor antagonists, calcium channel blockers and alpha blockers. The number of drugs to achieve blockbuster status in this sector runs into double figures and recent patent expiries have been characterised by the launch of multiple generics in this highly competitive market. This trend is likely to continue with, for example, the generic launch of the major anti-hypertensive drug ramipril onto the US market which is anticipated in October 2008.
The most widely prescribed drugs for cholesterol management are HMG-CoA reductase inhibitors, or statins. In terms of revenue, Pfizer’s Lipitor (atorvastatin) is the largest selling drug of any kind worldwide. Lipitor accounts for around 40% of the market for cholesterol management drugs by value. Without a viable replacement in the pipeline, Pfizer is keen to hold onto its Lipitor revenue for as long as possible. Ranbaxy is equally keen to launch generic atorvastatin in key markets and continues its worldwide patent litigation battle with Pfizer. While Pfizer should be able to fend off generic competition in the US at least until its basic patent expires in March 2010, Lipitor has also been facing competition from multiple entries of generic simvastatin.
The global hypertension drugs market is currently valued at around US$38.5 billion. The range of drug classes available to treat high blood pressure contributes to the competitive nature of a market in which there were 13 blockbuster drugs in 2006, with combined sales of US$25.8 billion. While competition among the multinationals is significant in this lucrative segment, the marketplace for generics is equally competitive. Typically, an anti-hypertensive going off patent is highly contested with multiple generic market entrants.
Sales forecasts to 2012 for major products
Companies active in the cardiovascular market are reviewed with respect to
Caraco Pharmaceutical Labs
More Cardiovascular reports by Espicom Healthcare Intelligence
Cardiology Point of Care Diagnostics: Products, players & outlook to 2017 by Espicom Healthcare Intelligence
Despite the economic situation and many operational challenges, the POC cardiology product sector is set to achieve growth of 7.8% ...
Diabetes Landscape: Market, Technology and Intellectual Property by Espicom Healthcare Intelligence
There are as many as 183 million people unaware that they have diabetes, including at least 78% of people with diabetes in Africa. In some ...
Global Causes of Death to 2020 by Espicom Healthcare Intelligence
With this report you can: Identify trends in 23 diseases/conditions and forecast patient population growth with data covering 2012-2020 Assess the current and future ...
Biomarkers: Applications and Trends by Espicom Healthcare IntelligenceSee all reports like this >>
Few would contest the need for pharmaceutical research to be productive. Despite significant increases in the cost of drug discovery and drug development, the number ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Diseases & Conditions
- Life Sciences
- Generics Drugs
- Therapeutic Area
- MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts
- Cardiac Fibrosis – Pipeline Review, H1 2013
- Arrhythmias – Pipeline Review, H1 2013
- Congestive Heart Failure (Heart Failure) – Pipeline Review, H1 2013
- MarketVIEW: Cholesterol vaccines (CAT No: VAMV045)